Juq-097 !new!

| Item | Details | |------|----------| | | JUQ‑097 (also referenced in some filings as JQ‑097 ). | | Developer | Janssen Pharmaceuticals (J&J) – the “JUQ” prefix follows Janssen’s internal naming convention for early‑stage CNS‑focused small‑molecule programs. | | Chemical class | Highly selective, non‑peptidic antagonist of the nociceptin/orphanin‑FQ peptide (NOP) receptor (also known as OPRL1 ). | | Molecular weight | ≈ 420 Da (exact value pending final publication). | | Formulation | Oral tablets (10 mg, 30 mg, 60 mg) for Phase II/III trials; a soluble‑capsule version is in pre‑clinical toxicology. | | Target indication(s) | Alcohol Use Disorder (AUD) and Major Depressive Disorder (MDD) with comorbid alcohol misuse . Secondary exploratory programs include opioid‑induced hyperalgesia and post‑traumatic stress disorder (PTSD). |

In a world where codes and ciphers have been used for centuries to conceal and reveal information, one particular sequence of characters has piqued the interest of many: JUQ-097. This enigmatic code has been shrouded in mystery, with its origins, meaning, and applications remaining largely unknown to the general public. As we embark on this investigative journey, we aim to shed light on the JUQ-097 phenomenon, exploring its possible connections to various fields and unraveling the secrets hidden within. JUQ-097